Skip to content

Advertisement

  • Poster presentations
  • Open Access

Uncovering the role of IFNAR1 in experimental cerebral malaria

  • 1 and
  • 1
Malaria Journal20109 (Suppl 2) :P3

https://doi.org/10.1186/1475-2875-9-S2-P3

  • Published:

Keywords

  • Interferon
  • Malaria
  • Plasmodium
  • Cerebral Malaria
  • Interferon Alpha

Cerebral malaria (CM) is a severe complicated form of malaria, resulting in an overwhelming inflammatory response in the brain due to infection from Plasmodium-falciparum[1]. Only a fraction of malaria infected individuals develop CM and it has been shown that both genetic and non-genetic factors determine CM susceptibility [2]. Variants in Interferon alpha receptor-1 (IFNAR1) have been associated with protection from CM in humans [3] and in susceptibility to severe forms of malaria, such as CM. As in humans, susceptibility of mice to CM is determined by genetic factors (unpublished data, Sambo et al).

Type-I Interferon, α/β (IFN-I), plays a key role in regulating the immune response through release of pro- and anti-inflammatory cytokines and stimulating antigen presentation and cellular cytotoxicity. Its expression has been found to be up regulated upon infection with viruses and bacteria, and can illicit protective or disease-aggravating effects [4]. From this knowledge we hypothesize that IFNAR1 is a determinant of the inflammatory response that leads to development of Experimental cerebral malaria (ECM).

Ifnar1-/- mice were infected with Plasmodium berghei ANKA (P.berghei ANKA) and assessed for survival and development of ECM. 70% of mice did not develop ECM and died 28-30 days later from anemia and hyper-parasitemia. Ifnar1-/- mice do not show a decrease in parasite burden, and display mild blood brain barrier breakage. We are currently investigating brain vasculature and infiltration of inflammatory molecules within these mice and are conducting transfer experiments using Ifnar1-/- and Rag2-/- mice with the aim of defining the role of IFNAR1 in development of ECM upon infection with P.berghei ANKA, and determining where and how this protection is inflicted.

Authors’ Affiliations

(1)
Disease Genetics Group, Instituto Gulbenkian de Ciência, Oeiras, Portugal

References

  1. Idro R, Jenkins NE, Newton CRJC: Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurology. 2005, 4: 827-40. 10.1016/S1474-4422(05)70247-7.View ArticlePubMedGoogle Scholar
  2. Bagot S, Campino S, Penha-Goncalves C, Pied S, Cazenave PA, Holmberg D: Identification of two cerebral malaria resistance loci using an inbred wild-derived mouse strain. PNAS. 2002, 15: 9919-9923. 10.1073/pnas.152215199.View ArticleGoogle Scholar
  3. Aucan C, Walley AJ, Hennig BJW, Fitness J, Frodsham A, Zhang L, Kwiatkowski D, Hill AVS: Interferon-alpha receptor-1 (IFNAR1) variants are associated with protection against cerebral malaria in The Gambia. Genes and Immunity. 2003, 4: 275-282. 10.1038/sj.gene.6363962.View ArticlePubMedGoogle Scholar
  4. Decker T, Muller M, Stockinger S: The yin and yang of type I interferon activity in bacterial infection. Nat. Rev. Immunol. 2005, 5: 675-687. 10.1038/nri1684.View ArticlePubMedGoogle Scholar

Copyright

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement